EOF方案联合脾多肽注射液治疗晚期胃癌的临床疗效

目的探讨EOF(表柔比星+奥沙利铂+5-氟尿嘧啶)方案联合脾多肽注射液治疗晚期胃癌患者临床疗效。方法前瞻性选取2016年3月至2018年3月来朝阳市第二医院治疗的120例晚期胃癌患者,按照随机数字表法将其分2组,其中单纯接受EOF方案治疗的60例患者设为对照组,同时接受EOF方案联合脾多肽注射液治疗的60例患者设为观察组,治疗1个疗程,共计6周。疗程结束后1周,比较2组患者的治疗总有效率、生活质量评分、血清肿瘤标志物以及免疫功能指标方面的差异。结果观察组患者的近期治疗总有效率66.67%,高于对照组的46.67%,差异有统计学意义(P <0.05)。观察组患者疗程结束后1周的心理健康、社会功能、物质生活、躯体功能评分分别为(80.18±6.55)、(83.84±6.99)、(83.84±6.99)、(77.99±5.62)分,均显著高于对照组(69.15±5.76)、(63.88±6.25)、(72.68±6.88)、(63.44±5.51)分],差异均有统计学意义(P <0.05)。观察组患者治疗后1周CD3+、CD4+、CD8+、NK细胞比率分别为(64.72±6.08)%、(53.68±7.26)%、(34.15±6.25)%、(37.11±7.23)%,均明显高于对照组(59.26±6.24)%、(47.70±0.26)%、(32.94±6.55)%、(27.01±7.13)%],差异均有统计学意义(P <0.05)。观察组患者化疗后不良反应的发生率10.00%,明显低于对照组的30.00%,差异有统计学意义(P <0.05)。结论对于晚期胃癌患者的治疗,选取EOF方案联合脾多肽注射液不仅能够在一定程度上提高治疗有效率,而且能够改善患者生活质量并提高其自身免疫力,降低化疗药物的不良反应,效果明显,可以在临床推广使用。

Comparative study of EOF regimen combined with Lienal Polypeptide Injection in the treatment of advanced gastric cancer

Objective To enhance the clinical efficacy and immunity of,patients with advanced gastric cancer and improve their quality of life,and explore the feasibility of EOF regimen combined with splenic polypeptide injection in the treatment of advanced gastric cancer. Methods This study was a prospective study. One hundred and twenty patients with advanced gastric cancer treated in the Second Hospital of Zhaoyang from March 2016 to March 2018 were selected as the research objects according to the sequence of patients’ hospitalization number,and 120 patients were divided into 2 groups by random number table method. Sixty patients who received EOF alone,namely epirubicin + oxaliplatin + 5-fluorouracil,were selected as control group. At the same time,60 patients who received EOF regimen(epirubicin + oxaliplatin + 5-fluorouracil) combined with Spleen Polypeptide Injection were set up as observation group. The treatment lasted 1 courses(6 weeks). The short-term total efficacy rate,quality of life scores,serum tumor markers and immune function indexes 1 week after the treatment were compared betwwen the two groups. Results The short-term total effective rate of the observation group was 66. 67%,much higher than that of the control group(46. 67%),and the difference was statistically significant(P < 0. 05). The scores of mental health,social function,material life,and physical function of the observation group were(80. 18 ± 6. 55),(83. 84 ± 6. 99),(83. 84 ± 6. 99),(77. 99 ± 5. 62) points,respectively,for one week after treatment,which were significantly higher than those of the control group (69. 15 ± 5. 76),(63. 88 ± 6. 25),(72. 68 ± 6. 88),(63. 44 ±5. 51) points],the differences were statistically significant(P < 0. 05). The ratios of CD3+,CD4+,CD8+and NK cells in the observation group were(64. 72 ± 6. 08) %,(53. 68 ± 7. 26) %,(34. 15 ± 6. 25) %,(37. 11 ± 7. 23) %,respectively,1 week after treatment,which were significantly higher than those of the control group (59. 26 ± 6. 24) %,(47. 70 ± 0. 26) %,(32. 94 ± 6. 55) %,(27. 01 ± 7. 13) % ],the differences were statistically significant(P < 0. 05). The incidence of adverse reactions of the observation group was 10. 00%,which was significantly lower than that of the control group(30. 00%),and the difference was statistically significant(P < 0. 05). Conclusion For the treatment of patients with advanced gastric cancer,the selection of EOF regimen combined with spleen polypeptide injection can not only improve the treatment efficiency to a certain extent,but also can improve the quality of life of patients and improve their own immunity,reduce the side effects of chemotherapy drugs,the effect is obvious,which can be widely used in clinical practice.